Leslie Hammersmith Young Survival Coalition Champaign-Urbana Thursday morning session: Clinical Connections from Bench to Bedside, Beckman Institute, 3:00 PM--3:30 PM Abstract: Medical research empowers us to fight cancer, and advocacy empowers us to ensure that it addresses the needs of people affected by cancer. Advocacy helps us get through our cancer experiences, stand up for all people affected by cancer and gain a feeling of control over our own healthcare. Young Survival Coalition has staked out a powerful role as the voice for young women affected by breast cancer. Our Champaign-Urbana affiliate supports young women in Central Illinois through their breast cancer diagnosis and treatment, and we actively work to become educated cancer research advocates so that we can help all young women and end cancer for all people. We work to raise awareness and make improvements on issues of unique importance to young women. Survivors have been instrumental in shaping cancer research studies by helping to define which questions researchers need to address in order to improve the standard of care and quality of life issues most important to us. Educated advocates provide a necessary perspective, making sure researchers think about how their work helps us. This talk discusses the connections between cancer survivorship, cancer research and accelerating our progress towards ending cancer. Speaker bio: Leslie Hammersmith is the eLearning Analyst in the Office of the Chief Information Officer at the University of Illinois Urbana-Champaign. She has over 14 years of experience in higher education and faculty development in educational technologies. Leslie is trained in Cancer Research Advocacy and is a Patient Advocate with Carle Cancer Center, where she reviews cancer research protocols. In 2009 Leslie was one of the founders of the Champaign-Urbana Affiliate of Young Survival Coalition, the premier global organization dedicated to the critical issues unique to young women who are diagnosed with breast cancer. Under her leadership, YSC C-U has grown to a recognized community organization to support young women facing breast cancer in Central Illinois. Leslie has participated in programs from Reasearch Advocacy Network and AACR Scientist Survivor Program, and continues to pursue professional development in advocacy.
Panel Discussion Please join us for a panel discussion on the social impact of cancer and how it affects patients, providers, clinicians, and researchers alike. We are fortunate to feature Leslie Hammersmith (moderator), Jennifer Smith, and Patience Anders from the local Young Survival Coalition, as well as an oncology nurse navigator, clinician, and researcher (names TBA). This diverse panel will discuss themes surrounding cancer diagnosis, care, and research, and we welcome the audience to contribute and participate throughout the event. Issues to be discussed include: (1) Patient Experience, (2) Clinical Strategies, (3) Research Motivation. Truly, this will be an informative and exploratory event for participants of all backgrounds. We hope this panel discussion will result in a highly interactive and dynamic dialogue between the panelists and members of the audience.
Jonathan D. Licht, M.D. Professor, School of Medicine (Hematology/Oncology), Northwestern University Robert H. Lurie Comprehensive Cancer Center, Northwestern University Friday morning session: Targeting Molecular Mechanisms for Personalized Therapeutics, Beckman Auditorium, 9:05 AM -- 9:50 AM Abstract: Abnormalities in the epigenetic regulation of chromatin structure and function can lead to aberrant gene expression and cancer development. Epigenetic regulators can be affected by chromosomal rearrangement, point mutations, deletions and amplifications in cancer. The result may be changes in the function of specific transcription factors and pathways or more global, genome wide changes in chromatin modification and gene expression. Consequently, epigenetic therapies aim to restore normal chromatin modification patterns through the inhibition of various components of the epigenetic machinery. Specific transcriptional targeting of hematological malignancies was achieved through the treatment of acute promyleocytic leukemia. More recently specific therapies have been developed against Bcl6 in lymphoma and MLL proteins in leukemia. Histone deacetylase and DNA methyltransferase inhibitors represent the first putative global epigenetic therapies, however these agents have pleiotropic effects and it remains unclear how they lead to therapeutic responses. More recently, drugs that inhibit histone methyltransferases were developed, perhaps representing more specific agents. I will review emerging epigenetic targets in cancer and present recent models of promising epigenetic therapies. Speaker bio: Dr. Licht is the Johanna Dobe Professor of Medicine, Chief, Division of Hematology/Oncology and an Associate Director (Clinical Sciences) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. For over 20 years, Dr. Licht's laboratory has studied aberrant transcriptional regulation as a cause of hematological malignancy. This has included the molecular biology of acute promyelocytic leukemia and transcriptional mechanisms and targets of the PLZF transcription factor. He has studied chromatin changes and gene expression mediated by the MMSET protein overexpressed in a subset of multiple myeloma, as well as aberrant gene and miRNA regulation in myeloproliferative neoplasms, and most recently chromatin changes mediated by EZH2 in lymphoma. Dr. Licht is the Principal Investigator of a Leukemia Society Specialized Center of Excellence grant on chromatin mechanisms in hematological malignancies and Senior Scientific Leader of the Northwestern University NCI-Funded Physical Sciences Oncology Center, also centered on aberrant chromatin regulation. Dr. Licht is a Senior Editor of Clinical Cancer Research and serves on the editorial boards of Oncogene, Clinical Epigenetics and Cancer Biology and Therapy. Dr. Licht is a member of the Basic Sciences Committee of the NCI Board of Scientific Counselors.
The Inhibitory Effects of the Antifibrotic Drug Halofuginone on Uterine Leiomyoma Smooth Muscle Cells Friday, April 6, 2012 • 9:50-10:05 AM Authors: Faezeh Koohestani*, Wenan Qiang, Takeshi Kurita, Maureen Getty, Jacob Schanks, Amy MacNeill, and Romana Nowak Uterine leiomyomas are the most prevalent benign tumors of the reproductive tract in women. Available treatments for leiomyomas are limited to surgical procedures or hormonal therapy, which are costly and have significant side effects. In an effort to develop alternative therapeutic strategies, we tested the drug halofuginone (HF) in primary leiomyoma smooth muscle cells (LSMCs) in vitro and in vivo. Our results show that treatment of LSMCs with 50nM HF in vitro caused a significant decrease in cell proliferation and expression of collagens, which are hallmarks of these tumors. These effects were also found to be mediated through the MAPK and SRC pathways. We next tested the inhibitory effects of HF in an in vivo leiomyoma-xenografted mouse model. Treatment of mice with 0.25 mg/kg/day HF for four weeks significantly reduced the size of tumors by 50% with no effect on body weight or overall health of the animals. HF also caused a decrease in cell proliferation and increased in apoptosis. Our findings demonstrate that the antifibrotic drug HF inhibits the growth of leiomyomas through its effects on major cell signaling pathways, and may lead to the development of HF as an efficient therapeutic strategy for treatment of these common tumors.
T Cell Receptors For Potential Cancer Immunotherapy Applications: Single Chain T Cell Receptors Circumvent Mispairing with Endogenous TCR and Mediate T Cell Activity Friday, April 6, 2012 • 10:05-10:20 AM Authors: David H. Aggen*, Adam S. Chervin, Carolina M. Soto, Thomas M. Schmitt, Boris Engels, Jennifer D. Stone, Sarah A. Richman, Kurt H. Piepenbrink, Brian M. Baker, Philip D. Greenberg, Hans Schreiber, and David M. Kranz To improve the immune response to cancer, gene therapy with tumor-specific T cell-receptors (TCRs) provides an attractive approach to effectively arm patients T cells for tumor cell destruction. A high-affinity TCR specific for an antigenic peptide-major histocompatibility complex (pepMHC) can be introduced into patients T cells in vitro, and transfer of transduced T cells could kill cancer cells. The promise of this approach is potentially hindered by mispairing of exogenous TCR chains with endogenous TCR chains that could generate mixed TCR-heterodimers with graft-vs-host specificities. To address the issue of 'mixed' TCR-heterodimers, we investigated the use of single-chain-TCRs (scTv) that lack constant-domains to avoid mispairing and compared activity of T cells expressing scTv relative to full-length TCR in vitro and in a murine tumor model. We demonstrated that the murine scTv m33, specific for a model tumor antigen pepMHC, mediated the activity of both CD4+ and CD8+ T cells with similar sensitivity to full-length m33 TCR. The scTv avoided mispairing with endogenous alpha-beta full-length TCRs and allowed for endogenous TCR surface expression at high levels. In a murine tumor model, CD8+ m33 scTv T cells persisted, whereas CD8+ m33 full-length TCR T cells were deleted, presumably by peripheral tolerance mechanisms.
Imaging Estrogen Receptors and Estrogen-Receptor Function in Breast Cancer by Positron Emission Tomography (PET): Improved Selection of Patients for Benefit from Endocrine Therapies Friday, April 6, 2012 • 10:45-11:00 AM Authors: John A. Katzenellenbogen*, Michael J. Welch, Farrokh Dehdashti, and Barry Siegel The growth of many breast cancers is regulated by estrogens, and these cancers can be treated effectively with endocrine therapies (ET). Identifying patients who will benefit from ET, however, continues to be challenging. Measurement of estrogen receptor (ER) levels in tumor biopsy samples using immunohistochemistry provides accurate negative prediction (no ER implies no ET response), but poor positive prediction. We have developed a fluorine-18 labeled estrogen, 16alpha-[F-18]fluoro-17beta-estradiol (FES) for in vivo imaging of ER in breast cancer by positron emission tomography (PET). Clinical PET imaging studies with FES provides a higher positive predictive value for benefit from ET than does IHC. In addition, an endocrine challenge test that measures the change in tumor metabolism, assessed by PET with 2-[F-18]fluoro-2-deoxyglucose (FDG) 1 week after tamoxifen or after 1 day of estradiol therapy, provides a highly accurate prediction of the ultimate benefit of ET in treatment. Both FES-PET and serial FDG-PET are promising approaches whereby it should be possible to tailor ET to individual breast cancer patients.
Thursday, April 5, 2012 • 2:15-2:30 PM Authors: Logan Carr*, Joseph Brancheck*, and Dhaval Patel Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer in the United States and accounts for 20 percent of non-melanoma skin cancers; in addition, it is the second most common cancer overall in Caucasians. Due to an aging population and increasing sun exposure, the number of cutaneous carcinomas is increasing and the incidence is estimated to be over three million annually. Unlike the more common basal cell carcinoma, SCCs are more likely to metastasize. This makes a timely diagnosis and treatment even more important because a long delay before surgical removal of SCC is associated with an increased risk of invasive SCC. SCC is already associated with a high cost and morbidity which becomes even higher when the cancer becomes invasive. The patient in this case did not have insurance and, therefore, delayed treatment of his SCC for two years. His treatment at two years required 8 hours of operation time and the expertise of a neurosurgeon, plastic surgeon, and otolaryngologist as well as many days of hospital stay. This case study exemplifies the advantage of primary and secondary prevention as well as the treatment of advanced head and neck SCCs.
John F. McDonald, Ph.D. Professor, School of Biology, Georgia Tech CSO Ovarian Cancer Institute, Georgia Tech Friday afternoon session: Bioinformatics and Systems Approaches to Cancer Treatment and Diagnostics, Beckman Auditorium, 3:25 PM -- 4:25 PM Abstract: The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with analytical chemistry, computer science/machine learning and material science/nanotechnology to develop novel approaches to the diagnosis and treatment of ovarian cancer. Speaker bio: In addition to his responsibilities as Associate Dean at Georgia Tech, Dr. McDonald also serves as Director of Tech's Integrated Cancer Research Center (ICRC). ICRC researchers are using the latest genomic- and nano-technologies to develop new and effective cancer diagnostics and therapeutics. Dr McDonald is the Chief Scientific Officer at the Ovarian Cancer Institute (Atlanta) and previously served as Head of the Genetics Department at the University of Georgia (Athens) and Chair of the School of Biology at Georgia Tech. Dr. McDonald is an Elected Fellow of American Association for the Advancement of Science (AAAS). He holds a PhD in Genetics from University of California, Davis, CA. and did his post-doctoral training at the University of California San Diego (La Jolla) and at the Institute for Cancer Research at Columbia University Medical School (New York).
Friday, April 6, 2012 • 2:30-2:45 PM Authors: Jack Pu Hou*, Pratik Lahiri, and Jian Ma One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple samples. However, it is now acknowledged that individual tumors of the same type are highly heterogeneous and have diverse genomic alterations. We developed a novel method, called DriveRank, to discover patient-specific molecular driver events. Our probabilistic model accounts for both gene interactions and somatic mutations, which allow us to quantitatively rank a list of mutations in any individual tumor based on mutations propensity to become advantageous alterations. DriveRank was applied to Glioblastoma, Ovarian Cancer, and Breast Cancer data from The Cancer Genome Atlas, and it was shown to rank proposed driver mutations from other predictive software accurately by displaying a median rank for candidate mutations to be over the 92 percentile for all three cancers. Our results showed that the usual suspects (TP53, EGFR, RB1, APC, etc..) appeared frequently along with rarer, yet functionally important, suspects not normally classified as drivers. The DriveRank method will potentially enable the determination the optimal treatment strategy for patients through individualized assessment.
Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents Richard B. Jones, Ph.D. Assistant Professor, Ben May Department for Cancer Research, University of Chicago Institute for Genomics and Systems Biology, University of Chicago Friday afternoon session: Bioinformatics and Systems Approaches to Cancer Treatment and Diagnostics, Beckman Auditorium, 1:30 PM -- 2:15 PM Abstract: A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have discovered many DNA variants that influence complex phenotypes such as response to anti-cancer chemo-therapeutic agents. Expression quantitative trait loci (eQTL) mapping techniques have subsequently been employed to identify gene candidates whose mRNA expression is affected by genomic variation and that may serve as missing links between genome variation and cell phenotypes. To improve our understanding of the genetic basis of differential response to anti-cancer chemotherapeutic agents, we quantified hundreds of cell signaling proteins and transcription factors in genotyped HapMap LCLs. We then identified many novel genome loci associated with protein expression and identified many novel proteins whose expression was correlated with cellular response to anti-cancer chemotherapeutic agents. We subsequently validated several of these proteins as novel causal agents whose expression influenced cell death in response to anti-cancer agents. In this talk, we will speak about our vision for using global micro-array based protein analysis approaches to further the goal of personalized medicine. Speaker bio: Dr. Jones is an Assistant Professor in the Ben May Department for Cancer Research at the University of Chicago. He is also a Core Fellow of the Institute for Genomics and Systems Biology and is a founder and director of the University of Chicago Micro-western array Protein Analysis Core Facility. Dr. Jones has a long-standing interest in the development of automated protein analysis technologies for interrogating the roles of protein systems in cancer biology. Dr. Jones received his undergraduate training at Indiana University. He received his Ph.D. at the Center for Cancer Biology and Nutrition through Texas A&M University. He trained at Harvard University as an NIH postdoctoral fellow where he participated in the development of protein microarray approaches for studying mapping human protein interaction networks. His lab has since developed the micro-western array methodology for the network-level interrogation of protein abundances and modification states. His lab has recently applied this methodology for identifying protein networks that underlie resistance to anti-cancer agents.
Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer Friday, April 6, 2012 • 3:10-3:25 PM Authors: Mary J. Laws*, Athilakshmi Kannan, Sandeep Pawar, Milan K. Bagchi, and Indrani C. Bagchi We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1 gene is selectively deleted in the anterior pituitary. The Esr1d/d mice form palpable ovarian tumors which display expression of ovarian epithelial tumor markers, cytokeratin 8, WT1 and PAX 8. Besides proliferating epithelial cells, tumors also contain an expanded population of stromal cells. The loss of negative-feedback regulation by estrogen at the level of pituitary led to elevated production of luteinizing hormone, which stimulated ovarian cells to enhance steroidogenesis. Interestingly, stromal cells of the tumor display a high level of P450 aromatase expression, suggesting that these cells acquired the ability to synthesize estrogen. In response to estrogen produced by the stromal cells, the Esr1 signaling is accentuated in the ovarian epithelial cells, triggering abnormal cell proliferation and tumorigenesis. Consistent with this hypothesis, treatment with letrozole, an inhibitor of P450 aromatase, led to a marked reduction in tumor volume when compared to controls. We have, therefore, developed an animal model of ovarian epithelial tumorigenesis, which will serve as a powerful tool for exploring the involvement of estrogen-dependent signaling pathways in the etiology of this cancer.
Closing Address & Awards at the 2012 Symposium for the Cancer Community at Illinois
Daniel A. Heller, Ph.D. Department of Chemical Engineering, MIT Koch Institute for Integrative Cancer Research, MIT Memorial Sloan-Kettering Cancer Center Thursday afternoon session: Clinical Connections from Bench to Bedside, Beckman Auditorium, 1:15 PM -- 2:00 PM Abstract: Metastasis, the spread of cancer cells from a primary tumor to seed secondary tumors in distant sites, is one of the greatest challenges in cancer treatment today. For many patients, by the time cancer is detected, metastasis has already occurred. Over 80% of patients diagnosed with lung cancer, for example, present with metastatic disease. Although cancer therapies are improving, many drugs are not reaching the sites of metastases. Methods that are effective for treating large, well-vascularized tumors may be inadequate when dealing with small clusters of disseminated malignant cells. As the biological mechanisms of metastasis are being unraveled, it is becoming clear that new approaches to treat this condition may become available. The expanding capabilities of the materials sciences, especially in targeting, detection and particle trafficking, will enable novel approaches to treat cancers even after metastatic dissemination. Although the first generation of nano/materials-based drugs has reached the clinic, future systems promise significant advances in targeting metastatic sites and earlier detection through more sensitive imaging techniques. Speaker bio: Daniel Heller is a Damon Runyon Fellow in Robert S. Langer's laboratory at the David H. Koch Institute for Integrative Cancer Research at MIT. He obtained his BA in History from Rice University in 2000 and a PhD in Chemistry from the University of Illinois in 2010. His work is focused on nanoscale tools for detecting and treating human diseases. He will enter a faculty position at the Memorial Sloan-Kettering Cancer Center and Cornell Medical School in New York City in 2012.
Chemical Imaging for Histopathology: An Emerging Route for Molecular and Structural Analysis of Tissues Thursday, April 5, 2012 • 2:00-2:15 PM Authors: Michael J Walsh (Speaker), David Mayerich, Suman Setty, Andre Kajdacsy-Balla, and Rohit Bhargava Mid-Infrared (IR) spectroscopic imaging is an emerging approach to derive chemical images from tissues based on their inherent biochemistry. Histologic diagnosis is the gold standard for evaluating the presence and severity of most diseases. Current histopathological techniques use of panel of special stains and immunohistochemistry (IHC) to assess tissue architecture, determine cell types present and to classify disease. Here, we report on the evaluation of an automated means to accurate histologic recognition using IR spectroscopic imaging. This method does not need dyes or probes and dispenses with human input but relies on computational approaches to provide decisions. Recent advances in IR spectroscopic imaging for tissue histopathology with a focus on breast cancer diagnosis will be presented. IR imaging coupled with computational approaches has the potential be a powerful adjunct to current histopathological procedures, with the ability to take a single unstained tissue section and give decisions on the cell types present and to provide novel chemical information to the pathologist in a useful format.
Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling Friday, April 6, 2012 • 11:00-11:15 AM Authors: Elvira de Mejia*, and Vermont Dia Lunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer metastasis using in vitro and in vivo colon cancer model of liver metastasis. Lunasin inhibited the activation of focal adhesion kinase by 28%, 39% and 60% in RKO, HCT-116 and KM12L4 human colon cancer cells, respectively. Lunasin caused an increase in the expression of the inhibitor of kappa B alpha, a decrease in nuclear p50 NF-kB and a reduction in the migration of cancer cells. Lunasin inhibited metastasis and potentiated the effect of oxaliplatin by reducing the expression of proliferating cell nuclear antigen. Liver metastatic nodules were reduced from 28 (PBS) to 14 (lunasin, p = 0.047) while combination of lunasin and oxaliplatin to 5 (p = 0.004). The tumor burden was reduced from 0.13 (PBS) to 0.10 (lunasin, p = 0.039) to 0.04 (lunasin-oxaliplatin, p less than 0.0001). The effect of oxaliplatin in modifying the expression of proteins involved in apoptosis and metastasis was potentiated by lunasin. Lunasin inhibited metastasis by direct binding with alpha-5 beta-1 integrin suppressing FAK/ERK/NF-kB signaling, and potentiated the effect of oxaliplatin in preventing the outgrowth of metastasis.
A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE) Friday, April 6, 2012 • 2:15-2:30 PM Authors: Jennifer D. Stone*, David H. Aggen, Hans Schreiber, and David M. Kranz Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against effective target epitopes. To overcome this problem, two approaches using antibodies against cancer-associated epitopes have been designed to re-direct T cell activity. In one approach, the binding domain (scFv) of an anti-cancer antibody is linked to intracellular signaling domains, yielding a chimeric antigen receptor (CAR) that is expressed on ex vivo-activated T cells for adoptive therapy. In the second approach, the anti-cancer scFv is fused to another scFv that binds the TCR/CD3 complex, yielding an injectable product called a bispecific T cell engager (BiTE). Here, we directly compared the sensitivity of each strategy directed against a unique tumor epitope on the transmembrane glycoprotein OTS8. While both approaches showed efficient anti-tumor activities, CAR-targeted T cells were consistently more sensitive than BiTE-targeted T cells to low numbers of antigens per target cell. Using a panel of targets with varying levels of OTS8, we have constructed a sensitivity scale, providing a guide for applying these approaches under various conditions.
















